skip to navigation skip to content skip to footer


Maloprim™ (dapsone/pyrimethamine) was registered in Australia for malaria prophylaxis in 1979. It was phased out in 1990 after increasing resistance in malaria parasites made it ineffective.

It was generally well tolerated although it could cause skin rashes or allergic reactions in some people. In higher doses (more than one tablet weekly) it could cause a fall in white blood cells (agranulocytosis), making the person more likely to get sick from infections. People who experienced this rare side effect got very sick within a few weeks of starting Maloprim. It resolved quickly after stopping the medication.

Maloprim is no longer available in Australia. The individual components, dapsone and pyrimethamine, are still used to treat other infections but not malaria.